Array BioPharma Inc. (NASDAQ: ARRY) today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The data, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma. ARRY-520 is a novel, first-in-class, highly potent, selective KSP inhibitor currently advancing into a single-agent Phase 2 clinical trial and combination trials in patients with multiple myeloma. The poster is available as a PDF on Array's website at www.arraybiopharma.com.
"Although KSP inhibitors have not been explored to date in myeloma, the early data from this study are yielding interesting and exciting results," said Sagar Lonial, MD, Associate Professor, Vice Chair of Clinical Affairs, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine. "Among a very heavily pretreated and relapsed and refractory patient population, ARRY-520 is well tolerated, and has resulted in sustained stable disease or partial remissions in a large number of patients. Since many novel agents show modest activity as single agents in such a refractory population, the preliminary evidence of activity with a manageable toxicity profile for ARRY-520 suggests that this agent should be further explored in larger trials both alone and in combination with other anti-myeloma agents."
Researchers discover how mutations disrupt protein splicing and cause disease